



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Agrawal	GROUP:	1635
SERIAL NO.:	09/412,947		
DOCKET NO.:	HYZ-050CP2	EXAMINER:	Epps, J.
FILING DATE:	October 5, 1999		
TITLE:	MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND METHODS OF THEIR USE		

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their attorney are aware of the following publications and information listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration.

Pursuant to 37 C.F.R. §1.97, Applicants hereby make of record the documents listed on the attached Form PTO-1449.

Copies of all the references listed on Form PTO-1449 are enclosed, except for the following:

1. Beaucage, in *Protocols for Oligonucleotides and Analogs: Synthesis and Properties*, Agrawal (ed.), Humana Press, Totowa, NJ, pp. 33-62 (1993)
2. Cadd et al., "Holoenzymes of cAMP-dependent protein kinase containing the neural form of type I regulatory subunit have an increased sensitivity to cyclic nucleotides." *J. Biol. Chem.*, Vol. 265, pp. 19502-19506 (1990)
3. Cheng et al., "An active twenty-amino-acid-residue peptide derived from the inhibitor protein of the cyclic AMP-dependent protein kinase." *Biochem J.*, Vol. 231, No. 3, pp. 655-661 (1985)
4. Cho-Chung, YS, "Hypothesis. Cyclic AMP and its receptor protein in tumor growth regulation in vivo." *J. Cyclic Nucleotide Res.*, Vol. 6, pp. 163-167 (1980)

5. Cho-Chung, YS, "Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy." *Cancer Res.*, Vol. 50, pp. 7093-7100 (1990)
6. Cho-Chung et al., *Curr. Opin. Thera. Patents*, Vol. 3, pp. 1737-1750 (1993)
7. Henry et al. *Pharm. Res.* 11: PPDM8082 (1994)
8. Iversen, *Antisense Research and Application* (Crooke, ed) CRC Press, 461 (1993)
9. Kabat and Mayer (eds), *Experimental Immunochemistry*, 2d Ed., Springfield, IL, CC Thomas, p. 125
10. Mantel, "Evaluation of survival data and two new rank order statistics arising in its consideration." *Cancer Chem. Rep.*, Vol. 50, No. 3, pp. 163-170 (1966)
11. *Remington's Pharmaceutical Sciences* (18th ed.) Genarro, ed., Mack Publishing Co., Easton, PA, (1990)
12. Rohlf et al., "8-Cl-cAMP induces truncation and down-regulation of the RI alpha subunit and up-regulation of the RII beta subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells." *J. Biol. Chem.*, Vol. 268, pp. 5774-5782 (1993)
13. Slapak et al. in *Harrison's Principles of Internal Medicine* (Isselbacher et al., eds.) McGraw-Hill, Inc., NY, pp. 1826-1850 (1994)
14. Uhler et al. "Expression of cDNAs for two isoforms of the catalytic subunit of cAMP-dependent protein kinase." *J. Biol. Chem.*, Vol. 262, pp. 15202-15207 (1987)

Those references are currently unavailable, however, Applicant will provide the copies of the above-mentioned references if requested by the examiner.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

This Information Disclosure is being filed after the mailing date of a first Office Action from the Patent and Trademark Office for the above-referenced application on the merits. Therefore, pursuant to 37. C.F.R. §1.17(p), Applicants hereby authorize the Patent and

Trademark Office to charge \$180.00 for the submission of the Information Disclosure Statement to our Deposit Account No. 08-0219.

There are no additional fees, however, if any fee is due please charge any costs to our Deposit Account No. 08-0219.

If there are any questions, please call the undersigned at the telephone number indicated below.

Respectfully submitted,

HALE AND DORR LLP



Ann-Louise Kerner, Ph.D.

Registration No. 33,523

Attorney for Applicants

March 26, 2001

60 State Street

Boston, MA 02109

(617) 526-6000

(617) 526-5000 (fax)

CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date indicated below.

Date: March 26, 2001

By: 

Tae H. Kim